SIA
UTHR icon

Strategic Investment Advisors’s United Therapeutics UTHR Stock Holding History

Strategic Investment Advisors’s Portfolio UTHR Stock Details UTHR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$4.93M Sell
9,090
-662
-7% -$373K 0.3% 49
2026
Q1 		$5.78M Buy
9,752
+1,662
+21% +$828K 0.4% 44
2025
Q4 		$3.95M Sell
8,090
-320
-4% -$149K 0.34% 50
2025
Q3 		$3.52M Sell
8,410
-339
-4% -$114K 0.32% 51
2025
Q2 		$2.51M Buy
8,749
+3,148
+56% +$941K 0.24% 51
2025
Q1 		$1.73M Sell
5,601
-382
-6% -$131K 0.18% 73
2024
Q4 		$2.11M Buy
5,983
+95
+2% +$34.9K 0.22% 56
2024
Q3 		$2.11M Buy
5,888
+4,034
+218% +$1.36M 0.23% 61
2024
Q2 		$591K Sell
1,854
-123
-6% -$32.6K 0.07% 160
2024
Q1 		$454K Buy
1,977
+118
+6% +$26.6K 0.06% 182
2023
Q4 		$409K Sell
1,859
-92
-5% -$21.2K 0.06% 183
2023
Q3 		$441K Buy
1,951
+37
+2% +$8.52K 0.07% 179
2023
Q2 		$423K Buy
1,914
+198
+12% +$43.9K 0.06% 145
2023
Q1 		$384K Buy
1,716
+661
+63% +$163K 0.07% 179
2022
Q4 		$293K Buy
+1,055
New +$266K 0.06% 192

Other funds holding UTHR

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $11.1B AUM 207.82% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
JT
Jupiter Topco New York $245B AUM
Norges Bank
Norges Bank Oslo, Norway $1T AUM

Strategic Investment Advisors's UTHR Position: Q2 2026 in Review

Strategic Investment Advisors reduced its United Therapeutics (UTHR) stake by 6.8% in Q2 2026, selling an estimated $373K and leaving 9,090 shares worth $4.93M. The position accounts for 0.3% of the portfolio, ranked #49.

Strategic Investment Advisors first reported a position in UTHR in Q4 2022 and has held it in 15 quarters since. The position peaked at $5.78M in Q1 2026. 878 funds tracked by Wall St. Rank hold UTHR as of Q2 2026.

  • Strategic Investment Advisors held 9,090 shares of United Therapeutics worth $4.93M as of Q2 2026.
  • Strategic Investment Advisors sold 662 United Therapeutics shares in Q2 2026, an estimated $373K.
  • United Therapeutics made up 0.3% of Strategic Investment Advisors's portfolio in Q2 2026, its #49 holding.
  • Strategic Investment Advisors first reported a position in United Therapeutics in Q4 2022 and has held it in 15 quarters since.
  • Strategic Investment Advisors's United Therapeutics position peaked at $5.78M in Q1 2026.
  • 878 funds tracked by Wall St. Rank held United Therapeutics as of Q2 2026.

Based on Strategic Investment Advisors's 13F filing for Q2 2026, filed 14 Aug 2026.